Oslo, Norway, February 15th, 2023 – AdjuTec Pharma AS is a privately held company developing antibiotic resistance breakers. The company is preparing the first-in-man study of its lead drug candidate APC148, end of this year. Embarking on the clinical phase 1 program will be a major achievement and inflexion point for the company. In 2-year time, the company will have documented a significant part of the efficacy and safety needed for a market authorisation. This will make Adjutec attractive to partners and strengthen the commercial positioning of company. To strengthen the support of partnering activities Adjutec is happy to announce that Ton Berkien has been elected to the company board.
Ton Berkien has a background from Saxion University of Applied Science, Scandinavian International Management Institute and Harvard Business School. He has worked 20 years in the international pharma industry in various companies including Amgen, Takeda/Nycomed and Ferring in business development and corporate development positions, covering licensing and M&A. His experience covers deal-making with J&J, Amgen and Almirall in territories including the US, Europe and a number of growth markets, e.g. China. At present he is CBO of Ultimovacs (Norway) and serves as Chairman of the Board of Gedea, a company in Lund, Sweden. Ton has a Dutch and Swedish nationality and lives in Sweden.
Ton Berkien has a background from Saxion University of Applied Science, Scandinavian International Management Institute and Harvard Business School. He has worked 20 years in the international pharma industry in various companies including Amgen, Takeda/Nycomed and Ferring in business development and corporate development positions, covering licensing and M&A. His experience covers deal-making with J&J, Amgen and Almirall in territories including the US, Europe and a number of growth markets, e.g. China. At present he is CBO of Ultimovacs (Norway) and serves as Chairman of the Board of Gedea, a company in Lund, Sweden. Ton has a Dutch and Swedish nationality and lives in Sweden.
“The main milestones for Adjutec in the coming 2-3 years is to secure funding and strike a deal with a partner to take APC148 to the market. The huge experience of Ton Berkien in deal-making including his investor network, will be of great value to Adjutec. We are looking forward to working with him on the board of the company”, comments Chair of Board Nicolaj Weiergang.
About antimicrobial resistance (AMR) – https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
AMR is a global health threat with an estimated 5mill associated deaths, including 1.27mill deaths attributable to bacterial AMR in 2019. WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials is the main driver in the development of drug-resistant pathogens. AMR results in prolonged hospital stays at intensive care units with increased costs to the healthcare system. Without effective antimicrobials, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.
About AdjuTec Pharma
AdjuTec Pharma is a company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The company technology offers a unique mechanism of action that inactivates bacterial defence enzymes and restores bacterial sensitivity to antibiotics. The company’s lead product is APC148, a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes. The technology was invented by Professor Pål Rongved and his group at the Department of Pharmacy, University of Oslo. The Company is located at St. Olavs gate 5, 0165 - downtown Oslo.
For more information, please visit www.adjutecpharma.com
Please contact: info@adjutecpharma.com
Follow us on LinkedIn and Twitter
AMR is a global health threat with an estimated 5mill associated deaths, including 1.27mill deaths attributable to bacterial AMR in 2019. WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials is the main driver in the development of drug-resistant pathogens. AMR results in prolonged hospital stays at intensive care units with increased costs to the healthcare system. Without effective antimicrobials, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.
About AdjuTec Pharma
AdjuTec Pharma is a company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The company technology offers a unique mechanism of action that inactivates bacterial defence enzymes and restores bacterial sensitivity to antibiotics. The company’s lead product is APC148, a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes. The technology was invented by Professor Pål Rongved and his group at the Department of Pharmacy, University of Oslo. The Company is located at St. Olavs gate 5, 0165 - downtown Oslo.
For more information, please visit www.adjutecpharma.com
Please contact: info@adjutecpharma.com
Follow us on LinkedIn and Twitter